The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDalata Hotel Gp Regulatory News (DAL)

Share Price Information for Dalata Hotel Gp (DAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 358.00
Bid: 330.00
Ask: 386.00
Change: 0.00 (0.00%)
Spread: 56.00 (16.97%)
Open: 358.00
High: 0.00
Low: 0.00
Prev. Close: 358.00
DAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Dalata Hotel Group PLC: Purchase of new London Hotel

16 Feb 2023 07:00

Dalata Hotel Group PLC (DAL,DHG) Dalata Hotel Group PLC: Purchase of new London Hotel 16-Feb-2023 / 07:00 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.


 

Dalata Hotel Group announces purchase of new London hotel for £44.3 million

The Group’s first Maldron Hotel in London

 

ISE: DHG              LSE: DAL

Dublin and London | 16 February 2023: Dalata Hotel Group plc ("Dalata" or "the Group"), the largest hotel operator in Ireland, with a growing presence in the United Kingdom and continental Europe, is pleased to announce the addition of a new 192-bedroom hotel at 240 Seven Sisters Road, Finsbury Park, North London to its hotel portfolio. Under the transaction, Dalata has acquired the entire issued share capital of Tide Developments (4) Limited (“TD4”) for a total consideration of £44.3 million (€49.7 million) from Furadino Holdings Limited. TD4 has a gross asset value of £45.1 million and owns the freehold interest of the hotel property. The total consideration will be financed from Dalata’s existing cash and banking facilities.

The newly finished hotel, which has never traded, consists of 192 bedrooms, ground floor lobby and a restaurant and bar. Prior to opening in summer 2023, Dalata will invest in excess of £2 million to enhance the property and launch under the Maldron brand. The hotel, with an expectation of stabilised annual earnings of £4 million, will be Dalata’s first Maldron hotel in London, its 18th hotel in the UK and will create over 50 jobs locally. Conveniently located within walking distance of the Emirates Stadium, the hotel is adjacent to Finsbury Park Station, with extensive National Rail, London Underground and bus services offering direct links to King’s Cross St Pancras and the centre of London.

The property was constructed using the Vision Modular System, which can result in as much as a 40 per cent saving in the embodied carbon emissions when compared with traditional methods of construction. The sustainably designed hotel is BER A rated, includes photovoltaic panels, and is expected to achieve BREEAM ‘Excellent’ accreditation.

Dermot Crowley, CEO, Dalata commented on the announcement:

“London is a key strategic growth market for Dalata. We are very excited to be opening our first Maldron hotel in the city in advance of our Maldron in Shoreditch which is currently under construction. This acquisition represents an outstanding opportunity to operate a new, sustainably built, hotel in a vibrant and developing area as we continue our ambitious UK expansion plan. The strength of our balance sheet has been a crucial element in enabling us to make this investment as we continue to create value for all of our stakeholders.”

Shane Casserly, Corporate Development Director, Dalata added:

“Acquiring a new hotel asset in London, in challenging funding markets, that will be operational in the summer of 2023, is a fantastic achievement by the Group. This transaction highlights our appetite for growth as well as the flexibility of our business model, which enables us to grow through acquisition, development and leasing. We are excited by the excellent sustainability credentials of the property as we continue to make progress on our ambitious targets.”

ENDS

 

About Dalata

Dalata Hotel Group plc was founded in August 2007, listed as a plc in March 2014 and is now Ireland’s largest hotel operator, with a growing presence in the UK and continental Europe. The Group operates two primary hotel brands, Clayton Hotels and Maldron Hotels. The Group’s portfolio comprises 50 primarily 4-star hotels situated in city-centre locations with over 10,950 rooms across 29 owned hotels, 18 leased hotels and three management contracts. The Group has ambitious expansion plans for the UK and continental Europe with a committed pipeline of over 1,300 rooms. For the first six months of 2022, Dalata reported revenue of €220.2 million and a profit after tax of €46.7 million. Dalata is listed on the Main Market of Euronext Dublin (DHG) and the London Stock Exchange (DAL). For further information visit: www.dalatahotelgroup.com

 

Contacts

Dalata Hotel Group plc

Tel +353 1 206 9400

Dermot Crowley, CEO

investorrelations@dalatahotelgroup.com

Shane Casserly, Corporate Development Director

Carol Phelan, CFO

 Graham White, Head of Investor Relations

 

Joint Company Brokers

 

Davy: Anthony Farrell

Tel +353 1 679 6363

Berenberg: Ben Wright

Tel +44 20 3753 3069

 

 

Investor Relations and PR | FTI Consulting

Tel +353 86 401 5250

Melanie Farrell

dalata@fticonsulting.com

 

__________________________

 

 


ISIN:IE00BJMZDW83, IE00BJMZDW83
Category Code:ACQ
TIDM:DAL,DHG
LEI Code:635400L2CWET7ONOBJ04
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.:223503
EQS News ID:1561077
 
End of AnnouncementEQS News Service

UK Regulatory announcement transmitted by EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
23rd Oct 201910:27 amRNSHolding(s) in Company
8th Oct 20197:00 amRNSDirectorate Change
4th Oct 20199:47 amRNSHolding(s) in Company
3rd Oct 20194:25 pmRNSHolding(s) in Company
3rd Oct 20194:03 pmRNSHolding(s) in Company
3rd Oct 20192:30 pmRNSDirector/PDMR Shareholding
1st Oct 20191:33 pmRNSTotal Voting Rights
4th Sep 20192:59 pmRNSDirector/PDMR Shareholding
4th Sep 20197:00 amRNSDirector/PDMR Shareholding
4th Sep 20197:00 amRNSDirector/PDMR Shareholding
3rd Sep 20191:05 pmRNSDirector/PDMR Shareholding
3rd Sep 20197:00 amRNSHalf-year Report
2nd Sep 20192:23 pmRNSTotal Voting Rights
29th Aug 20193:45 pmRNSHolding(s) in Company
23rd Aug 20198:55 amRNSDirector Declaration
1st Aug 20199:16 amRNSTotal Voting Rights
30th Jul 20197:00 amRNSNotice of Results
11th Jul 20195:35 pmRNSHolding(s) in Company
10th Jul 201910:33 amRNSHolding(s) in Company
4th Jul 201910:57 amRNSBlock listing Interim Review
4th Jul 20199:44 amRNSHolding(s) in Company
1st Jul 20199:11 amRNSTotal Voting Rights
21st Jun 20197:00 amRNSEuronext Dublin Market Notice
20th Jun 20199:00 amRNSBlock listing application
4th Jun 20199:08 amRNSTotal Voting Rights
31st May 201910:05 amRNSHolding(s) in Company
2nd May 20194:54 pmRNSResult of AGM
2nd May 20197:00 amRNSAGM Statement
1st May 201910:01 amRNSTotal Voting Rights
10th Apr 20194:33 pmRNSDirector/PDMR Shareholding
8th Apr 20197:00 amRNSEuronext Dublin Market Notice
5th Apr 201910:21 amRNSAdditional Listing
1st Apr 20194:39 pmRNSNotice of AGM
1st Apr 201910:21 amRNSTotal Voting Rights
21st Mar 20192:37 pmRNSAnnual Financial Report
20th Mar 201912:19 pmRNSHolding(s) in Company
19th Mar 201911:41 amRNSHolding(s) in Company
11th Mar 20191:05 pmRNSDirector/PDMR Shareholding - Replacement
11th Mar 201911:41 amRNSDirector/PDMR Shareholding
6th Mar 201910:57 amRNSHolding(s) in Company
4th Mar 201911:24 amRNSHolding(s) in Company
1st Mar 20198:47 amRNSTotal Voting Rights
26th Feb 20197:00 amRNSFinal Results
12th Feb 20193:59 pmRNSHolding(s) in Company
1st Feb 20199:10 amRNSTotal Voting Rights
21st Jan 20197:00 amRNSAcquisition
8th Jan 201910:45 amRNSNotice of Results
7th Jan 20194:29 pmRNSBlock listing Interim Review
3rd Jan 201912:24 pmRNSAcquisition
2nd Jan 201912:16 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.